Jim Garrison, a social and political activist and author, will be featured in a Praxis Peace Institute online event focusing ...

London singer, composer, and producer Lauren Auder has revealed the details of her upcoming second album, Whole World as ...

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy pipeline. Ulixacaltamide’s Essential3 data appear statistically robust, but a ...

Praxis specializes in using genetic insights to discover new therapies for neurological disorders. The biotech's efforts received a boost today when the U.S. Food and Drug Administration (FDA) granted ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor. Praxis on ...

Praxis Precision Medicines (PRAX) just hit a double inflection point, with its EMBOLD trial for relutrigine stopped early for efficacy and a successful pre-NDA meeting for ulixacaltamide setting up a ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) stock rose Friday after the company shared results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of ...

If your 2025 YouTube history is a mashup of music videos, cooking clips, sports highlights and late-night "how did I get here?" rabbit holes, then there is a new way for you to look back at your year ...

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Praxis' fortunes have ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...